Hunan Er-Kang Pharmaceutical Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Qingrong Sun

Amministratore delegato

CN¥335.7k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	5yrs
Proprietà del CEO	n/a
Durata media del management	5yrs
Durata media del Consiglio di amministrazione	3.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Qingrong Sun (38 yo)

5yrs

Mandato

CN¥335,700

Compensazione

Mr. Qingrong Sun is General Manager of Hunan Er-Kang Pharmaceutical Co., Ltd from November 14, 2019 and serves as Director from November 14, 2022. He joined Hunan Er-Kang Pharmaceutical Co., Ltd. in July 2...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Qingrong Sun	GM & Non-Independent Director	5yrs	CN¥335.70k	Nessun dato
Zhao Xun	CFO & Non Independent Director	no data	CN¥389.10k	Nessun dato
Xiangyang Shi	Deputy GM & Non Independent Director	no data	CN¥535.10k	Nessun dato
Jishun Gu	Deputy GM & Board Secretary	4.7yrs	CN¥514.20k	0.0017% CN¥ 108.0k
Licheng Zhang	Deputy General Manager	no data	CN¥422.70k	Nessun dato
Wang Hui	Deputy General Manager	5yrs	CN¥365.30k	Nessun dato

5.0yrs

Durata media

42.5yo

Età media

Gestione esperta: Il team dirigenziale di 300267 è esperto e expertise (durata media dell'incarico 5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Qingrong Sun	GM & Non-Independent Director	2yrs	CN¥335.70k	Nessun dato
Zhao Xun	CFO & Non Independent Director	5yrs	CN¥389.10k	Nessun dato
Xiangyang Shi	Deputy GM & Non Independent Director	6.2yrs	CN¥535.10k	Nessun dato
Fangwen Shuai	Chairman of the Board	no data	CN¥512.60k	41.38% CN¥ 2.6b
Junwen Wang	Independent Director	5yrs	CN¥150.00k	Nessun dato
Wuzhen Jiang	Independent Director	5yrs	CN¥150.00k	Nessun dato
Qing Peng	Chairman of Supervisory Board	3.5yrs	Nessun dato	Nessun dato
Xue Tan	Independent Director	2yrs	CN¥150.00k	Nessun dato
Haiyi Li	Non-Employee Supervisor	2yrs	Nessun dato	Nessun dato
Hong Wang	Supervisor	2yrs	Nessun dato	Nessun dato

3.5yrs

Durata media

50yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 300267 sono considerati esperti (durata media dell'incarico 3.5 anni).

Hunan Er-Kang Pharmaceutical Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Hunan Er-Kang Pharmaceutical Co., Ltd, Annual General Meeting, May 17, 2024

Hunan Er-Kang Pharmaceutical Co., Ltd Announces Executive Changes

Insufficient new directors

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings released: CN¥0.015 loss per share (vs CN¥0.006 loss in 3Q 2023)

New major risk - Share price stability

Hunan Er-Kang Pharmaceutical Co., Ltd to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings released: EPS: CN¥0.002 (vs CN¥0.013 in 2Q 2023)

New minor risk - Share price stability

Hunan Er-Kang Pharmaceutical Co., Ltd to Report First Half, 2024 Results on Aug 29, 2024

Hunan Er-Kang Pharmaceutical Co., Ltd, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: CN¥0.095 loss per share (vs CN¥0.022 profit in FY 2022)

Hunan Er-Kang Pharmaceutical Co., Ltd to Report Q1, 2024 Results on Apr 27, 2024

Hunan Er-Kang Pharmaceutical Co., Ltd to Report Fiscal Year 2023 Results on Apr 25, 2024

Third quarter 2023 earnings released

Second quarter 2023 earnings released: EPS: CN¥0.013 (vs CN¥0.004 in 2Q 2022)

Hunan Er-Kang Pharmaceutical Co., Ltd Announces 2022 Final Profit Distribution, Payable on 09 June 2023

Hunan Er-Kang Pharmaceutical Co., Ltd Approves 2022 Profit Distribution Plan

First quarter 2023 earnings released: EPS: CN¥0.013 (vs CN¥0.011 in 1Q 2022)

Hunan Er-Kang Pharmaceutical Co., Ltd Announces Executive Changes

Insufficient new directors

Third quarter 2022 earnings released: EPS: CN¥0.003 (vs CN¥0.026 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.004 (vs CN¥0.024 in 2Q 2021)

Full year 2021 earnings released: CN¥0.38 loss per share (vs CN¥0.098 profit in FY 2020)

High number of new and inexperienced directors

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.026 (vs CN¥0.056 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.024 (vs CN¥0.021 in 2Q 2020)

Hunan Er-Kang Pharmaceutical Co., Ltd Announces 2020 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 09, June 2021

Hunan Er-Kang Pharmaceutical Co., Ltd Approves Final Cash Dividend for the Year 2020

First quarter 2021 earnings released: EPS CN¥0.026 (vs CN¥0.012 in 1Q 2020)

Hunan Er-Kang Pharmaceutical Co., Ltd Proposes Final Cash Dividend for the Year 2020

New 90-day low: CN¥3.79

New 90-day low: CN¥4.17

New 90-day low: CN¥4.62

Third quarter earnings released

Huang Shubiao, Xiao Qingguang, Wu Kaijian, and Huang Linggang completed the acquisition of 95% stake in Guangdong Yueerkang Pharmaceutical Co., Ltd. from Hunan Er-Kang Pharmaceutical Co., Ltd (SZSE:300267).

New 90-day high - CN¥5.23

First half earnings released

Hunan Er-Kang Pharmaceutical Co., Ltd to Report First Half, 2020 Results on Aug 28, 2020

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media